Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2022-12-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事对第四届董事会第二十三次会议事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 24th meeting of the 4th board of directors of Ruikang Pharmaceutical Group Co., Ltd. It discusses the 2022 employee stock ownership plan and its management measures, confirming compliance with relevant laws and regulations and recommending submission to the shareholders' meeting. The document is a formal opinion related to board meeting matters, not a full report, financial statement, or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions on company governance matters.
2022-12-06 Chinese
关于召开2022年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2022 third extraordinary general meeting of shareholders for 瑞康医药集团股份有限公司. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items, and proxy authorization forms. There is no financial data, earnings, or audit information presented. The document is not a report itself but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-12-06 Chinese
瑞康医药集团股份有限公司2022年员工持股计划管理办法
Governance Information Classification · 95% confidence The document is titled "2022 年员工持股计划管理办法" which translates to "2022 Employee Stock Ownership Plan Management Measures". It details the purpose, principles, participants, funding, management, rights and obligations, risk prevention, asset composition, and equity disposal related to the company's employee stock ownership plan. The content is a comprehensive management and operational guideline for the employee stock ownership plan, including legal compliance, governance structure, and procedural rules. It is not a financial report, earnings release, or announcement of voting results. It is a detailed internal governance document related to the company's employee stock ownership plan. Therefore, it fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-12-06 Chinese
第四届监事会第二十二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 22nd meeting of the 4th Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of the 2022 Employee Stock Ownership Plan (ESOP) draft and its management measures. The document includes voting results and states that the proposals will be submitted to the 2022 third extraordinary general meeting for approval. The content focuses on governance and employee incentive plans rather than financial results or detailed reports. The document length is short (1667 characters) and it is an announcement of meeting resolutions rather than a full report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or management bodies.
2022-12-06 Chinese
第四届董事会第二十四次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.). It details decisions related to the company's 2022 employee stock ownership plan, including approval of the plan draft, management measures, authorization for the board to handle related matters, and the scheduling of a shareholders' meeting to approve these matters. The document includes voting results and procedural details but does not contain financial statements or detailed financial data. It is a formal announcement of board decisions rather than a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-12-06 Chinese
瑞康医药2022年员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of an employee stock ownership plan (员工持股计划) for the year 2022 by 瑞康医药集团股份有限公司. It includes comprehensive information about the plan's purpose, participants, stock scale, funding sources, lock-up periods, performance assessments, management, and accounting treatment. The document is lengthy (15,000 characters) and contains substantive content about the plan itself, not merely an announcement or a brief summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a detailed plan document related to employee stock ownership, which is a form of capital/financing update concerning the company's capital structure and employee incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-12-06 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.